drugset / Trial / NCT03540355

Efficacy and Safety of Cipros 20 Association on Dyslipidemia Treatment

NCT03540355

Phase 3 Completed 406 enrolled EMS
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of Cipros 20 association in the treatment of dyslipidemia treatment.

Timeline

Start
2021-03-02
Primary completion
2025-01-23
Completion
2025-01-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Cipros 20 association Unknown Oral
Comparator Rosuvastatin Small molecule 20 mg Oral

Indications